NOX4 and diabetes mellitus: In a rat model of diabetic cardiomyopathy using streptozotocin-induced diabetes, treatment with antisense oligonucleotides targeting NOX4 attenuated NOX activity, NOX4 protein expression and ROS generation in the left ventricle, and improved cardiac systolic dysfunction [15].